The venture capital story of mid-2026 is no longer about lightweight software. The biggest checks are flowing toward companies solving bottlenecks in the physical world: space, defense, energy, and advanced computing in a decisive shift that’s reshaping how investors think about risk.
The clearest example came from orbital logistics. Impulse Space raised a $500 million in Series D backed by Founders Fund, Lux Capital, and others, in a round that values the company at $4.26 billion and brings its total capital raised to more than $1 billion. The pitch is that launch is no longer the only bottleneck in the commercial space economy — the next strategic layer is mobility after launch, with the company already flying multiple missions and holding hundreds of millions of dollars in customer contracts. Defense technology also drew major capital. Mach Industries raised a $300 million in Series C from investors including Sequoia Capital and Khosla Ventures, reflecting growing investor appetite for autonomous systems and advanced manufacturing.
Quantum computing notched one of the largest European raises. Oxford Quantum Circuits closed a £260 million Series C backed by a broad syndicate including the British Business Bank, Oxford Science Enterprises, and Chevron Technology Ventures.
The enterprise software that is attracting money increasingly has real revenue behind it. AlphaSense closed a $350 million round valuing the company at $7.5 billion, nearly double its previous $4 billion valuation after exceeding $600 million in annual recurring revenue and serving more than 7,000 global enterprises, including over 70% of the S&P 500. Observability firm Coralogix raised a $200 million Series F at a $1.6 billion valuation just 11 months after its previous round, a fast cadence even by current infrastructure standards.
The thread connecting these bets is what some investors call the return of “physical and operational friction” to venture underwriting. AI demand is pulling capital toward energy, grid infrastructure, and critical minerals because those are now part of the compute story in 2026. “Software” no longer means investors can ignore power, networks, sensors, or biology. Even biotech reflects this, with AI-native company Waypoint Bio raising a $20 million Series A to design next-generation CAR T therapies for solid tumors using spatial biology and computer vision.
For founders, the signal is clear: capital is available, but it’s concentrating around companies that address tangible, hard-to-replicate bottlenecks rather than abstract software plays.
This article is for informational purposes and does not constitute investment advice.
